Anticancer activity of pristimerin in ovarian carcinoma cells is mediated through the inhibition of prosurvival Akt/NF-κB/mTOR signaling

Journal of Experimental Therapeutics and Oncology

Volumn 10, Issue 4, 2014, Pages 275-283

  Gao, Xiaohua ^a   Liu, Yongbo ^a   Deeb, Dorrah ^a   Arbab, Ali S ^a   Gautam, Subhash C ^a,b  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b Surgical Research 4D   (United States)

Author keywords

Akt; Apoptosis; mTOR; Nf b; Ovarian cancer; Pristimerin

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PRISTIMERIN; PROCASPASE 3; PROCASPASE 8; PROCASPASE 9; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; SURVIVIN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TRITERPENE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL LINE; CELL DEATH; CELL MEMBRANE DEPOLARIZATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; MITOCHONDRIAL MEMBRANE POTENTIAL; OVARY CARCINOMA; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CARCINOMA; DRUG EFFECTS; METABOLISM; MITOCHONDRION; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MITOCHONDRIA; NF-KAPPA B; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRITERPENES;

EID: 84910107406     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ovarian Cancer: National Cancer Institute. http://www.cancer.gov/#fragment-1. Retrieved 07-25, 2013.
2. th edition. Philadelphia, PA: Lippincott Williams & Wilkins, 443-451, 2005.
3. Du Bois A, Neijt JP, Thigpen JT, First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer-a new standard of care? Ann Oncol 10: 35-41, 1999.
4. Neijt JP, Engelholm SA, Tuxen MK, et al, Exploratory Phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18: 3084-3092, 2000.
5. Buffa Filho W, Corcino J, Bolzani da SV, Furlan M, Pereira AM, Franca SC. Quantitative determination for cytotoxic Friedo-noroleanane derivatives from five morphological types of Maytenus ilicifolia (Celastraceae) by reverse-phase high-performance liquid chromatography. Phytochem Anal 13: 75-78, 2002.
6. Chang FR, Hayashi K, Chen IH, Liaw CC, Bastow KF, Nakanishi Y, Nozaki H, Cragg GM, Wu YC, Lee KH. Antitumor agents. 228. five new agarofurans, Reissantins A-E, and cytotoxic principles from Reissantia buchananii. J Nat Prod 66: 1416-20, 2003.
7. Dirsch VM, Kiemer AK, Wagner H, Vollmar AM. The triterpenoid quinonemethide pristimerin inhibits induction of inducible nitric oxide synthase in murine macrophages. Eur J Pharmacol 336: 211-7, 1997.
8. Figueiredo JN, Räz B, Séquin U. Novel quinone methides from Salacia kraussii with in vitro antimalarial activity. J Nat Prod. 61:718-23, 1998.
9. Brinker AM, Ma J, Lipsky PE, Raskin I. Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry 68: 732-66, 2007.
10. Costa PM, Ferreira PM, Bolzani Vda S, Furlan M, de Freitas Formenton Macedo Dos Santos VA, Corsino J, de Moraes MO, Costa-Lotufo LV, Montenegro RC, Pessoa C. Antiproliferative activity of pristimerin isolated from Maytenus ilicifolia (Celastraceae) in human HL-60 cells. Toxicol In Vitro 22: 854-63, 2008.
11. Yang H, Landis-Piwowar KR, Lu D, Yuan P, Li L, Reddy GP, Yuan X, Dou QP. Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells. J Cell Biochem103: 234-44, 2008.
12. Yan YY, Bai JP, Xie Y, Yu JZ, Ma CG. The triterpenoid pristimerin induces U87 glioma cell apoptosis through reactive oxygen species-mediated mitochondrial dysfunction. Oncol Lett. 5: 242-248, 2013.
13. Lee JS, Yoon IS, Lee MS, Cha EY, Thuong PT, Diep TT, Kim JR. Anticancer activity of pristimerin in epidermal growth factor receptor 2-positive SKBR3 human breast cancer cells. Biol Pharm Bull 36: 316-25, 2013.
14. Wu CC, Chan ML, Chen WY, Tsai CY, Chang FR, Wu YC. Pristimerin induces caspase-dependent apoptosis in MDA-MB- 231 cells via direct effects on mitochondria. Mol Cancer Ther. 4: 1277-85, 2005.
15. Lu Z, Jin Y, Chen C, Li J, Cao Q, Pan J. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl. Mol Cancer 9: 112, 2010.
16. Byun JY, Kim MJ, Eum DY, Yoon CH, Seo WD, Park KH, Hyun JW, Lee YS, Lee JS, Yoon MY, Lee SJ. Reactive oxygen species-dependent activation of Bax and poly(ADP-ribose) polymerase-1 is required for mitochondrial cell death induced by triterpenoid pristimerin in human cervical cancer cells. Mol Pharmacol 76: 734-44, 2009.
17. Wang Y, Zhou Y, Zhou H, Jia G, Liu J, Han B, Cheng Z, Jiang H, Pan S, Sun B. Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells.PLoS One 7, 2012.
18. Mu XM, Shi W, Sun LX, Li H, Wang YR, Jiang ZZ, Zhang LY. Pristimerin inhibits breast cancer cell migration by upregulating regulator of G protein signaling 4 expression. Asian Pac J Cancer Prev 13: 1097-104, 2012.
19. Mu X, Shi W, Sun L, Li H, Jiang Z, Zhang L. Pristimerin, a triterpenoid, inhibits tumor angiogenesis by targeting VEGFR2 activation. Molecules 17: 6854-68, 2012.
20. Sun X-M, MacFarlane M, Zhuang J, et al. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem 1999; 274: 5053-5060.
21. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 281: 305-1308, 1998.
22. Samuels Y and Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18: 77-82, 2006.
23. Mayo MW, Baldwin AS. The transcription factor NF-κB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 1470: M55-M62, 2000.
24. Vignot S, Faivre S, Aguirre D, et al. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncology 16: 525-537, 2005.